1 Title Page Title: Longer-term safety and efficacy of emtricitabine and tenofovir alafenamide versus emtricitabine and tenofovir disoproxil fumarate for HIV-1 Pre-exposure Prophylaxis: Week 96 results from a randomized, double-blind, placebo-controlled phase 3 trial Authors: Onyema Ogbuagu 1 , Peter J. Ruane 2 , Daniel Podzamczer 3 , Laura C. Salazar 4 , Keith Henry 5 , David M. Asmuth 6 , David Wohl 7 , Richard Gilson 8 , Yongwu Shao 9 , Ramin Ebrahimi 9 , Stephanie Cox 9 , Alexander Kintu 9 , Christoph Carter 9 , Moupali Das 9 , Jared M. Baeten 9 , Diana M. Brainard 9 , Gary Whitlock 10 , Jason M. Brunetta 11 , Gitte Kronborg 12 , Christoph D. Spinner 13 on behalf of DISCOVER study team. Affiliations: 1 Yale University, School of Medicine, New Haven, CT [O Ogbuagu MD] 2 Medical and Liver Health Institute, Los Angeles, CA [PJ Ruane MD] 3 Hospital Universitario de Bellvitge, Infectious Disease Department, HIV and STI Unit, Barcelona, Spain (Prof D Podzamczer MD] 4 Hoag Medical Group, Newport Beach, CA [LC Salazar MD]; 5 Hennepin Healthcare Research Institute, Minneapolis, MN [K Henry MD] 6 University of California Davis, School of Medicine, Davis, CA [Prof DM Asmuth MD] 7 University of North Carolina at Chapel Hill, Department of Medicine, Chapel Hill, NC [Prof D Wohl MD] 8 University College London, London, UK [Prof R Gilson MD]